You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

second cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Cancer, Primary Cancer, Second Cancer Trial in Lyon (Dostarlimab)

Not yet recruiting
  • Recurrent Cancer
  • +2 more
  • Lyon, France
    Centre Léon Bérard
May 12, 2023

Can Second Resection for pT1 Bladder Cancer be Avoided After

Recruiting
  • Bladder Cancer Stage I
  • Avoid second resection after initial complete resection
  • Mansoura, Dakahlia, Egypt
    Urology and nephrology center, Mansoura University
Aug 2, 2023

Progression-free Survival Trial (Sovalteinib Solutumab Tegeo)

Not yet recruiting
  • Progression-free Survival
  • Sovalteinib Solutumab Tegeo
  • (no location specified)
Jul 24, 2023

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

Second Line Treatment of Gastric Cancer Trial (Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan)

Not yet recruiting
  • Second Line Treatment of Gastric Cancer
  • (no location specified)
Dec 20, 2022

Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)

Recruiting
  • Cervical Cancer Recurrent
  • RC48 + Tislelizumab
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 25, 2023

Colorectal Cancer Trial in Changsha (fruquintinib and FOLFIRI)

Not yet recruiting
  • Colorectal Cancer
  • fruquintinib and FOLFIRI
  • Changsha, Hunan, China
    Hunan Cancer hospital
Apr 24, 2023

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Recruiting
  • Gastric Cancer
  • Fruquintinib, TAS102
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • (no location specified)
Dec 26, 2022

Second Cancer, Survivorship, Fertility Issues Trial in Amsterdam (No intervention ; observational)

Recruiting
  • Second Cancer
  • +6 more
  • No intervention ; observational
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoekziekenhuis
Feb 11, 2022

Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Nov 27, 2022

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,

Not yet recruiting
  • Metastatic Gastric Adenocarcinoma
  • +2 more
  • nal-IRI /Experimental
  • +2 more
  • (no location specified)
Jun 25, 2023

Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)

Not yet recruiting
  • Recurrent Liver Cancer After Liver Transplantation
  • Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
  • (no location specified)
Apr 17, 2023

HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • trastuzumab, bevacizumab with paclitaxel (triple combination)
  • (no location specified)
Dec 6, 2022

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

Not yet recruiting
  • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery Fudan University Shanghai Caner
Feb 22, 2023

Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)

Recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • Experimental drug
  • Control Rx
  • Hefei, Anhui, China
  • +11 more
Mar 13, 2023

Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin combined with Sintilimab
  • (no location specified)
Jul 2, 2023

Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)

Not yet recruiting
  • Metastatic Triple-negative Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023

Gastric Cancer Trial (Fruquintinib, Irinotecan)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Dec 6, 2022

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Colorectal Cancer Trial (Regorafenib)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 17, 2023

Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

Recruiting
  • Breast Cancer Stage IV
  • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
  • Mansoura, Dakahlia, Egypt
    Oncology center mansoura university
Jan 1, 2023

Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,

Not yet recruiting
  • Pancreatic Acinar Cell Carcinoma
  • +6 more
  • Nab paclitaxel
  • +5 more
  • (no location specified)
Oct 30, 2023